Exelixis Inc

Find Ratings Reports
EXEL : NASDAQ : Health Care
$17.37 | %
Today's Range: 16.42 - 17.74
Avg. Daily Volume: 6974900.0
12/02/16 - 4:00 PM ET

Financial Analysis


EXELIXIS INC's gross profit margin for the third quarter of its fiscal year 2016 has significantly increased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth. EXELIXIS INC is extremely liquid. Currently, the Quick Ratio is 2.04 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.

At the same time, stockholders' equity ("net worth") has greatly increased by 143.14% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q3 FY16 Q3 FY15
Net Sales ($mil)62.199.85
EBITDA ($mil)7.32-35.12
EBIT ($mil)7.02-35.5
Net Income ($mil)-11.28-45.54


Balance Sheet Q3 FY16 Q3 FY15
Cash & Equiv. ($mil)319.68197.81
Total Assets ($mil)548.49363.24
Total Debt ($mil)190.86377.89
Equity ($mil)32.02-74.23


Profitability Q3 FY16 Q3 FY15
Gross Profit Margin11.77-356.4
EBITDA Margin11.76-356.4
Operating Margin11.29-360.25
Sales Turnover0.230.1
Return on Assets-27.16-49.03
Return on Equity-465.260.0
Debt Q3 FY16 Q3 FY15
Current Ratio2.093.71
Debt/Capital0.861.24
Interest Expense7.8310.04
Interest Coverage0.9-3.54


Share Data Q3 FY16 Q3 FY15
Shares outstanding (mil)286.12226.15
Div / share0.00.0
EPS-0.04-0.21
Book value / share0.11-0.33
Institutional Own % n/a n/a
Avg Daily Volume6815329.06252496.0

Valuation


SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 149.69 indicates a significant premium versus the S&P 500 average of 2.79 and a significant premium versus the industry average of 11.17. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, EXELIXIS INC proves to trade at a premium to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
EXEL NM Peers 34.27   EXEL 60.53 Peers 28.50

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

EXEL's P/E is negative making this valuation measure meaningless.

 

Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

EXEL is trading at a significant premium to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
EXEL 304.55 Peers 40.16   EXEL NA Peers 0.44

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

EXEL's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
EXEL 149.69 Peers 11.17   EXEL 29.22 Peers 2.62

Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

EXEL is trading at a significant premium to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

EXEL is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
EXEL 38.71 Peers 170.51   EXEL 257.96 Peers 481.80

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

EXEL is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

EXEL significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades